Genfit S.A.

Paris Stock Exchange GNFT.PA

Genfit S.A. Inventory for the year ending December 31, 2023: USD 4.42 K

Genfit S.A. Inventory is USD 4.42 K for the year ending December 31, 2023, a 3.16% change year over year. Inventory is the value of goods held by a company for sale or used in the production process.

Genfit S.A. Inventory for the year ending December 31, 2022 was USD 4.28 K, a -6.01% change year over year.
Genfit S.A. Inventory for the year ending December 31, 2021 was USD 4.55 K, a -6.81% change year over year.
Genfit S.A. Inventory for the year ending December 31, 2020 was USD 4.89 K, a 8.85% change year over year.
Genfit S.A. Inventory for the year ending December 31, 2019 was USD 4.49 K, a -1.94% change year over year.

Key data

Date	Inventory	Goodwill	Total Assets	Current Liabilities

Paris Stock Exchange: GNFT.PA

Genfit S.A.

CEO	Mr. M. Pascal Prigent
IPO Date	Dec. 19, 2006
Location	France
Headquarters	Parc EurasantE
Employees	169
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

Key trends

Past 5 years